Relmada Therapeutics (RLMD) Profit After Tax (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Profit After Tax data on file, last reported at -$19.1 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 8.5% year-over-year to -$19.1 million in Q1 2026; TTM through Mar 2026 was -$58.9 million, a 22.23% increase from a year earlier, with the FY2025 full-year figure at -$57.4 million, up 28.25% from the prior year.
• Profit After Tax for Q1 2026 stood at -$19.1 million, up from -$19.9 million in the prior quarter.
• Over the last five years, Profit After Tax for RLMD reached as high as -$9.9 million in Q2 2025 and fell as low as -$39.9 million in Q2 2022.
• Historically, Profit After Tax has averaged -$24.3 million across 5 years, with a median of -$21.8 million in 2024.
• Across the five-year window, Profit After Tax slumped 78.91% in 2022 and soared 53.55% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$37.9 million in 2022, then soared by 33.68% to -$25.2 million in 2023, then gained by 25.86% to -$18.7 million in 2024, then slipped by 6.49% to -$19.9 million in 2025, then rose by 4.11% to -$19.1 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$19.1 million in Q1 2026, -$19.9 million in Q4 2025, and -$10.1 million in Q3 2025.